1-2 of 2
Fadi G. Haddad
Close
Sort by
Journal Articles

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Clinical Trials & Observations
Nicholas J. Short, Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Fadi G. Haddad, Zhenhua Li, Yu-Chih Hsiao, Jun J. Yang, Naveen Pemmaraju, Maro Ohanian, William G. Wierda, Guillermo Montalban-Bravo, Gautam Borthakur, Lina Han, Lianchun Xiao, Xuelin Huang, Regina Abramova, Min Zhao, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian
Journal: Blood Advances
Blood Adv (2024) 8 (4): 909–915.
https://doi.org/10.1182/bloodadvances.2023012231
Published: 2024
Includes: Supplemental data
Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Alexandre Bazinet, Tapan Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang, Sanam Loghavi, Jeffrey Jorgensen, Keyur Patel, Courtney DiNardo, Naval Daver, Yesid Alvarado, Fadi G. Haddad, Sherry Pierce, Graciela Nogueras Gonzalez, Abhishek Maiti, Koji Sasaki, Musa Yilmaz, Philip Thompson, William Wierda, Guillermo Garcia-Manero, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3284–3296.
https://doi.org/10.1182/bloodadvances.2022009391
Published: 2023
Includes: Supplemental data